Applied Molecular Transport Inc. AMTI
We take great care to ensure that the data presented and summarized in this overview for Applied Molecular Transport Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMTI
View allLatest Institutional Activity in AMTI
Top Purchases
Top Sells
About AMTI
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Transactions at AMTI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Epiq Capital Group, LLC |
SELL
Other acquisition or disposition
|
Indirect |
8,337,518
-67.54%
|
-
|
|
Dec 27
2023
|
Aaron Van Devender Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
212,659
-100.0%
|
-
|
|
Dec 27
2023
|
Shawn Cross CEO & Chair of the Board |
SELL
Sale (or disposition) back to the issuer
|
Direct |
545,499
-100.0%
|
-
|
|
Dec 27
2023
|
Brandon Hants CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
301,225
-100.0%
|
-
|
|
Dec 27
2023
|
Tahir Ph.D. Mahmood Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,600,000
-100.0%
|
-
|
|
Dec 27
2023
|
Tahir Ph.D. Mahmood Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
484,738
-100.0%
|
-
|
|
Nov 22
2023
|
Tahir Ph.D. Mahmood Director |
SELL
Open market or private sale
|
Direct |
286,320
-37.13%
|
$0
$0.16 P/Share
|
|
Nov 22
2023
|
Brandon Hants CFO |
SELL
Open market or private sale
|
Direct |
61,494
-16.95%
|
$0
$0.16 P/Share
|
|
Nov 22
2023
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
110,802
-16.88%
|
$0
$0.16 P/Share
|
|
Nov 15
2023
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
90,447
-12.11%
|
$0
$0.16 P/Share
|
|
Nov 15
2023
|
Brandon Hants CFO |
SELL
Open market or private sale
|
Direct |
50,146
-12.15%
|
$0
$0.16 P/Share
|
|
Oct 06
2023
|
Tahir Ph.D. Mahmood Director |
SELL
Open market or private sale
|
Direct |
184,442
-19.3%
|
$0
$0.16 P/Share
|
|
Oct 05
2023
|
Tahir Ph.D. Mahmood Director |
BUY
Grant, award, or other acquisition
|
Direct |
886,111
+48.12%
|
-
|
|
Sep 29
2023
|
Brandon Hants CFO |
SELL
Open market or private sale
|
Direct |
107,540
-20.55%
|
$0
$0.16 P/Share
|
|
Sep 29
2023
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
193,960
-20.5%
|
$0
$0.16 P/Share
|
|
Sep 28
2023
|
Brandon Hants CFO |
BUY
Grant, award, or other acquisition
|
Direct |
491,111
+48.41%
|
-
|
|
Sep 28
2023
|
Shawn Cross CEO & Chair of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
886,111
+48.36%
|
-
|
|
Sep 05
2023
|
Tahir Ph.D. Mahmood Director |
SELL
Open market or private sale
|
Direct |
2,245
-3.13%
|
$0
$0.21 P/Share
|
|
Sep 05
2023
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
1,253
-0.17%
|
$0
$0.21 P/Share
|
|
Sep 05
2023
|
Brandon Hants CFO |
SELL
Open market or private sale
|
Direct |
718
-0.17%
|
$0
$0.21 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 8.34M shares |
|---|---|
| Sale (or disposition) back to the issuer | 5.14M shares |
| Open market or private sale | 459K shares |